



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 20 Mar 2023 (#12)

Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take *4-18 months*, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Important Notices

[NOT-ES-23-009](#) Notice of Changes to RFA-ES-23-007 "Exploratory Grants for Climate Change and Health Research Center Development (P20 Clinical Trial Optional)" The purpose of this notice is to inform potential applicants of corrections to the Funding Opportunity Description for [RFA-ES-23-007](#)

[NOT-MH-23-195](#) Notice of Intent to Publish Funding Opportunity Announcement for Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) Mechanism (U01 Clinical Trial Optional)

[NOT-MH-23-210](#) Notice of Intent to Publish a Funding Opportunity Announcement for Biotypes of CNS complications in people living with HIV (P01 Clinical Trial Not Allowed)

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-23-019](#)

Type:U19

Application Due Date: June 08, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications to participate in the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network. The purpose of this FOA is to establish comprehensive, cooperative basic and translational research Centers to carry out in-depth research on prototype members of select virus families that have the potential to emerge as pandemic pathogens. The goal of these Centers will be to develop vaccine and monoclonal antibody strategies for prototype pathogen(s) that can be applied to closely related family members based on shared functional and structural properties. This FOA solicits for Centers proposing research on virus families from Flaviviridae and Togaviridae to be part of the ReVAMPP Network.

Budget: NIAID intends to commit ~\$15-30M in FY2024 to fund 1-2 awards. Funding in subsequent years is subject to the availability of funds. Application budgets are not expected to exceed \$10M direct costs/year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

2. Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-23-020](#)

Type:U19

Application Due Date: June 08, 2023 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications to participate in the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network. The purpose of this FOA is to establish comprehensive, cooperative basic and translational research Centers to carry out in-depth research on prototype members of select virus families that have the potential to emerge as pandemic pathogens. The goal of these Centers will be to develop vaccine and monoclonal antibody strategies for prototype pathogen(s) that can be applied to closely related family members based on shared functional and structural properties. This FOA solicits for centers proposing research on virus families from Bunyavirales, Paramyxoviridae and Picornaviridae to be part of the ReVAMPP Network.

Budget: NIAID intends to commit ~\$70-85M in FY2024 to fund 5-6 awards. Funding in subsequent years is subject to the availability of funds. Application budgets are not expected to exceed \$10M direct costs/year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

3. Systematic Review of Clinical Outcome Assessments (COAs) for Communication Brain-Computer Interface Devices (cBCIs) in Amyotrophic Lateral Sclerosis (ALS) (UH2/UH3) Clinical Trials Not Allowed

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-23-030](#)

Type: UH2/UH3

Application Due Date: May 24, 2023, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this funding opportunity is to solicit applications for UH2/UH3 cooperative agreements to support and inform the future development and use of COAs for cBCIs in patients with amyotrophic lateral sclerosis (ALS). The UH2/UH3 cooperative agreement involves two milestone driven phases: 1) the UH2 Phase will include a systematic landscape analysis of the available literature, relevant data sources, and interviews with key opinion leaders (KOLs) to document COAs for cBCIs used clinically and identify gaps between current COAs used in cBCI studies and other outcome measures that could demonstrate functional benefits for ALS patients with severe communication limitations; 2) the UH3 phase will consist of patient and caregiver focus groups to collect information about symptoms, functional status, and perceived benefits/risks of cBCIs. Each phase will have a limit of 1 year for a total award period of 2 years. The UH2/UH3 application must be submitted as a single application, and applicants should note specific instructions for each phase in this FOA.

Budget: Application budgets need to reflect actual needs of the proposed project and should not exceed the following total costs (direct and indirect) and maximum years of support:

YR 01 (UH2 Phase): \$200,000

YR 02 (UH3 Phase): \$300,000

4. BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-NS-24-004](#)

Type: R01

Application Due Date: June 30, 2023 through to January 20, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. Preliminary feasibility data are not required, and it is expected that the proposed research may be high-risk, but if successful could profoundly change the course of neuroscience research.

Applications may propose development of instrumentation hardware and/or devices and associated software, and/or molecular constructs for sensing and manipulating neural activity. Approaches may utilize any modality such as optical, electrical, magnetic, or acoustic recording/manipulation, to target neuronal electrical signals or other forms of neural activity, including intracellular signaling and engagement of non-neuronal cells in circuit function.

A companion FOA ([RFA-NS-24-005](#)) is targeted to projects focused on optimization of instrumentation and devices that are later in the development cycle, where iterative optimization and end-user testing is needed. The companion FOA does not allow projects primarily focused on development or optimization of molecular constructs for recording and manipulating neural activity. Projects of this nature are supported by this FOA and other BRAIN Initiative announcements including [RFA-MH-22-245](#), [RFA-MH-21-175](#), and [RFA-EY-21-001](#).

For this and the companion FOA, the aim of the proposed technologies should be to reduce major barriers to conducting neurobiological experiments, including considerations of cost and ease of access, and to enable new discoveries for understanding neural circuit function. Technologies should address major challenges associated with recording and modulating CNS activity, at cellular or circuit resolution, and should contribute to an overall ecosystem of technologies spanning multiple spatial and temporal scales in any region throughout the CNS. The approaches should be compatible with experiments in behaving animals, with an expectation that they will be validated with *in vivo* experiments during the course of the project. Proposed validation experiments must focus on demonstrating the capabilities and potential impact of the technology, rather than advancing the state of biological knowledge as the primary project goal. Applications are encouraged to integrate multiple approaches, and where appropriate, to leverage diverse domains of expertise from biological, chemical, and physical sciences, engineering, computational modeling, and statistical analysis.

This FOA requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

Budget: Issuing IC and partner [components](#) intend to commit an estimated total of \$10,000,000 per year to fund 15-20 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 3 years.

Research Development and Support Division (RDSD) &
Grants Management Office (GMO)
Faculty of Medicine and Health Sciences
Kth Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105